| 1 | Full title: Development and validation of a nomogram for predicting overall |
|----|--|
| 2 | survival of patients with ischemic cardiomyopathy and heart failure: a post-hoc |
| 3 | analysis of the Surgical Treatments for Ischemic Heart Failure (STICH) trail. |
| 4 | |
| 5 | Authors: |
| 6 | Pengju Guo [*] , MD, PhD; Chang He, MD; Junlei Li, MD, PhD; Youxu Jiang, MD, PhD; |
| 7 | Feng Wang, MD; Jiaxiang Wang, MD; Bin Lin, MD; Deguang Feng, MD. |
| 8 | |
| 9 | Pengju Guo, Department of Cardiovascular surgery, the First Affiliated Hospital of |
| 10 | Zhengzhou University, Zhengzhou, Henan 450000, People's Republic of China, |
| 11 | fccguopj@zzu.edu.cn |
| 12 | Chang He, Department of Cardiovascular surgery, the First Affiliated Hospital of |
| 13 | Zhengzhou University, Zhengzhou, Henan 450000, People's Republic of China, |
| 14 | hchleo@yeah.net |
| 15 | Junlei Li, Department of Cardiology, the First Affiliated Hospital of Zhengzhou |
| 16 | University, Zhengzhou, Henan 450000, People's Republic of China, |
| 17 | junleizzu@163.com |
| 18 | Youxu Jiang, Department of Cardiology, the Second Affiliated Hospital of |
| 19 | Zhengzhou University, Zhengzhou, Henan 450000, People's Republic of China, |
| 20 | doctorjyx@163.com |
| 21 | Feng Wang, Department of Cardiovascular surgery, the First Affiliated Hospital of |
| | |

22 Zhengzhou University, Zhengzhou, Henan 450000, People's Republic of China,

23 wangfeng171620@163.com

- Jiaxiang Wang, Department of Cardiovascular surgery, the First Affiliated Hospital of
- 25 Zhengzhou University, Zhengzhou, Henan 450000, People's Republic of China,
- 26 wangjiaxiang171619@163.com
- 27 Bin Lin, Department of Cardiovascular surgery, the First Affiliated Hospital of
- 28 Zhengzhou University, Zhengzhou, Henan 450000, People's Republic of China,
- 29 <u>linbin171621@163.com</u>
- 30 Deguang Feng, Department of Cardiovascular surgery, the First Affiliated Hospital of
- 31 Zhengzhou University, Zhengzhou, Henan 450000, People's Republic of China,
- 32 fengdeguang171618@163.com
- 33
- 34 **Shout title:** STICH trail: Nomogram to predict overall survival.
- 35
- 36 * Corresponding author:
- 37 Pengju Guo, fccguopi@zzu.edu.cn; address: No.1 Jianshe Dong Road, ErQi District,
- 38 Zhengzhou, Henan, China.
- 39
- 40 **Total word count:** 5931
- 41

42 Development and validation of a nomogram for predicting overall survival of 43 patients with ischemic cardiomyopathy and heart failure: a post-hoc analysis of

44 the Surgical Treatments for Ischemic Heart Failure (STICH) trail.

45

46 Abstract

47 **Purpose:** To establish a nomogram for predicting the overall survival (OS) of patients
48 with ischemic cardiomyopathy and heart failure based on the Surgical Treatment for
49 Ischemic Heart Failure (STICH) trail.

50 **Methods**: Patients who had valid key variables in the hypothesis 1 were included and 51 randomly divided into the training and validation groups (7:3 ratio). Using Cox 52 proportional hazards model, predictors for the OS in training group were identified 53 and integrated to establish a nomogram for predicting 1-year, 3-year, 5-year, and 54 ten-year survival probability. The nomogram performance was evaluated using 55 Harrell's concordance index (C-index), time-dependent receiver operating 56 characteristic curve, decision curve analysis, and Kaplan-Meier survival analysis.

Results: 940 of 1212 patients who had valid key variables were included. Seven predictors, including treatment type, gender, estimated glomerular filtration rate, Charlson co-morbidity index, 6-minute walk, end-systolic volume index and mitral regurgitation class were identified to establish the nomogram. The C-indices of the nomogram were 0.641 (95% CI: 0.627-0.655) and 0.649 (95% CI: 0.627-0.671) for training and validation groups, respectively. The calibration curves revealed consistency between predicted and observed survival. The area under 1-year, 3-year,

| 64 | 5-year, and ten-year OS receiver operating characteristic curves were 0.634, 0.616, |
|----|--|
| 65 | 0.630 and 0.638 in the training group, respectively. Decision curve analysis showed |
| 66 | effective net benefits of the model in clinical decision-making. Divided by the cutoff |
| 67 | values of prognostic indices, low-risk patients showed better OS than those with high |
| 68 | risk in training and validation groups (both p < 0.0001). |
| 69 | Conclusion: The current nomogram can effectively predict the OS of patients with |
| 70 | ischemic cardiomyopathy and heart failure, provide information about multidisciplinary |
| 71 | therapeutic that may prolong the survival time, and serve as a perfect tool in |
| 72 | conjunction with the STS and EuroSCORE II risk models in clinical decision making. |
| 73 | |
| | |

- 74 **Keywords**: Ischemic cardiomyopathy; Heart failure; Coronary artery bypass grafting;
- 75 Survival; STICH
- 76

77 Nonstandard Acronyms and Abbreviations

| OS | overall survival |
|------|------------------------------------|
| ICM | ischemic cardiomyopathy |
| CABG | coronary artery bypass grafting |
| PCI | percutaneous coronary intervention |
| LVEF | left ventricular ejection fraction |
| CAD | coronary artery disease |
| NYHA | New York Heart Association |
| MR | mitral regurgitation |

| ESVI | end-systolic volume index |
|---------|---|
| eGFR | estimated glomerular filtration rate |
| CKD-EPI | Chronic Kidney Disease Epidemiology Collaboration |
| CCI | Charlson co-morbidity index |
| MED | medical |
| IQR | interquartile range |
| ROC | receiver operating characteristic |
| DCA | Decision Curve Analysis |
| HR | hazards ratio |
| CI | confidence interval |
| AUC | area under curve |

78

80 **1. Introduction**

81 Multifaceted strategies to address the control of worldwide prevalence of ischemic cardiomyopathy (ICM) and heart failure, which are projected to affect 8 million US 82 population by 2030, have progressively gained advances during last decades.¹ 83 Coronary artery bypass grafting (CABG) has become the preferred recommendation 84 85 for patients with ICM and heart failure in contemporary guidelines with decreasing heterogeneous consensus.²⁻⁴ However, the realistic concern of triple risk of death 86 87 within the initial 30 days after randomization among patients who underwent CABG plus medical therapy compared with those received medical therapy alone, identified 88 by the Surgical Treatment for Ischemic Heart Failure (STICH) trial, makes the 89 ultimate clinical decision requiring courage to take a crucial step.^{5,6} This trend toward 90 conservation has resulted the overzealous use of percutaneous coronary intervention 91 92 (PCI) by nearly triple usage higher than CABG at clinician discretion, but without high-quality evidence.^{7,8} Due to the Society of Thoracic Surgeons (STS) and 93 94 EuroSCORE II risk models were developed to estimate the early postoperative 95 mortality. the long-term survival in this difficult management but life-prolonging entity can be hardly predicted.^{9,10} Similarly, given the extensive coexisting 96 comorbidities among patients with ICM and heart failure, a dilemma surrounding the 97 98 implement of the SYNTAX (Synergy Between PCI with TAXUS and Cardiac Surgery) score II 2020 is the interobserver variability and absence of clinical variables, which 99 may largely compromise the generalizability of the model.^{11,12} 100

Landmark results of the STICH trail have driven progress in our understanding of

this specific cohort.^{5,13} In the setting of contemporary era of personalized medicine, clinical decision should be patient-centered, which can be achieved through the ascertainment and quantification of survival probability with the engagement of clinicians and patients. However, to the best of our knowledge, there is no specific risk model to predict the overall survival (OS) of patients with ICM and heart failure. Accordingly, we constructed a nomogram based on clinical variables derived from the STICH trail to predict the OS of this specific cohort.

109

110 **2. Methods**

111 **2.1 Patient source**

112 The current study was a post-hoc analysis of the STICH trail (funded by the 113 National Institutes of Health, NCT00023595), and approved by the National Heart, 114 Lung, and Blood Institute and our institutional review board (2022-KY-1409-002). The 115 data was accessed via the Biologic Specimen and Data Repository Information 116 Coordinating Center. The STICH trail and extended follow-up have previously reported in detail.^{5,14} Among 1212 patients with an left ventricular ejection fraction 117 118 $(LVEF) \le 35\%$ and coronary artery disease (CAD) amenable to CABG in hypothesis 1, 119 940 patients, who had valid preoperative information of age, gender, race, New York 120 Heart Association (NYHA) heart function class, medical history, mitral regurgitation (MR) class, previous revascularization (CABG or PCI), distance of 6-minute walk, 121 122 LVEF, left ventricular end-systolic volume index (ESVI), Duke CAD index, creatinine, and follow-up information of treatment received, days from randomization to CABG, 123

years of follow-up time, and patients status at the last follow-up, were included in the
current study. The detail screening process of patients was shown in Figure 1. The
eligible cases were randomly stratified into training and validation groups (7:3 ratio).
Each patient provided written informed consent and the investigation complied with
the principles outlined in the Declaration of Helsinki.

129 **2.2 Measurable variables and outcomes**

130 For ease of comparison, age (\leq 50, 51 - 60, 61 - 70, and \geq 71 years), 6-minute 131 walk (≤ 300 and > 300m), LVEF (≤ 20%, 21 – 25%, 26 – 30%, and 31 – 35%), ESVI (≤ 60, 61 – 90, and \geq 90 ml/m²), and Duke CAD Index (\leq 40, 41 – 70, 71 – 100) were 132 133 translated into categorical variables. The estimated glomerular filtration rate (eGFR) 134 was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation, and then categorized as > 60 ml/min per $1.73m^2$ or ≤ 60 ml/min 135 per 1.73m^{2.15} The Charlson co-morbidity index (CCI) for each patient was accounted 136 based on medical history.^{16,17} 137

Considering the predictive nature of the model, patients who received CABG within 90 days after randomization were assigned to the CABG group (CABG + MED) in the current study, and to medical group (MED) otherwise regardless of whether CABG was implemented exceeding 90 days after randomization. The patient status at the last follow-up was screened and OS was considered as the primary outcome of interest. The duration of survival was defined as the date from randomization to the data of death or last contact.

145 **2.3 Statistical analysis**

medRxiv preprint doi: https://doi.org/10.1101/2023.10.04.23296574; this version posted October 5, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Baseline characteristics were described by frequencies and percentages for categorical variables and by medians (interquartile range [IQR]) for continuous variables. Baseline differences between training and validation groups were compared using Chi-square or Fisher's exact tests for categorical variable. Univariate and multivariate Cox proportional hazards models were performed to identify the independent predictors for OS in the training group.

152 Based on the predictors identified by multivariate Cox proportional hazards model, 153 current nomogram was developed to predict the 1-year, 3-year, 5-year, and ten-year 154 survival probability of patients with ICM and heart failure. Harrell's concordance index 155 (C-index) and time-dependent receiver operating characteristic (ROC) curve were 156 used to evaluated the discrimination of the nomogram for predicting the survival 157 outcomes between different patients. The differences between predicted and actual 158 risks were visualized using calibration curves. Bootstraps with 1000 resamples were 159 performed to calculate the C-indices and plot calibration curves. The net benefit of the 160 nomogram for decision-making was evaluated using Decision Curve Analysis (DCA). 161 The prognostic index of 1-year OS for each patient was calculated using independent 162 predictors and corresponding hazards ratio. Based on the cutoff values of prognostic 163 indices, the training and validation groups were stratified into high-risk and low-risk 164 groups, respectively. Kaplan-Meier survival analysis and log rank test were used to 165 compare the OS between high-risk and low-risk groups.

All statistical analyses were conducted using R software (version 4.2.2,
 http://www.r-project.org/) and two-sided. Statistical significance was set at P < 0.05.

168

169 **3. Results**

3.1. Baseline characteristics

171 A total of 940 patients who had valid key variables were included, and randomly 172 stratified into training group (660 cases) and validation group (280 cases) based on 173 7:3 ratio. The baseline characteristics of entire cohort, training and validation groups 174 were showed in the Table 1. There was no significant difference between training and 175 validation groups with regard to each variable. The median follow-up time was 7.3 years (IQR: 2.9 - 9.4 years) for training group and 6.7 years (IQR: 3.2 - 9.3 years) for 176 validation group. There were 406 and 177 deaths recorded in the training and 177 178 validation groups, respectively.

3.2. Identification of the independent predictors

Univariate and multivariate Cox proportional hazards models were performed to identify the independent predictors for OS in the training group. In the multivariate analysis, seven variables, including treatment type (P = 0.032), gender (P < 0.001), eGFR (P = 0.018), CCI score (P = 0.002), 6-minute walk (P = 0.040), ESVI (P = 0.006) and MR class (P < 0.001) were identified as the independent predictors for OS (Table 2).

3.3. Nomogram establishment and verification

The 1-year, 3-year, 5-year, and ten-year predictive nomogram of OS for patients with ICM and heart failure were established after incorporating the seven independent predictors in the multivariate Cox proportional hazards model. (Figure. 2)

medRxiv preprint doi: https://doi.org/10.1101/2023.10.04.23296574; this version posted October 5, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

190 Using bootstraps with 1000 resamples, the C-indices of the nomogram were 0.641 191 (95% CI: 0.627-0.655) and 0.649 (95% CI: 0.627-0.671) for training and validation 192 groups, respectively. The predicted and actual risks of 1-year, 3-year, 5-year, and 193 ten-year OS were consistent as shown in the calibration curves (Figure. 3). The 194 values of area under curve (AUC) were 0.634, 0.616, 0.630 and 0.638 for 1-year, 195 3-year, 5-year and ten-year ROC curves in the training group, respectively (Figure. 4). 196 DCA curves identified the 1-year, 3-year, 5-year and ten-year net benefits during the 197 clinical application of the nomogram in decision-making for patients with ICM and 198 heart failure in training and validation groups (Figure. 5). Of note, a tangible elevated 199 trend of net benefit was shown with the extension of predicted nodal time in DCA curves. The prognostic index of 1-year OS for each patient calculated by the 200 201 independent predictors and corresponding hazards ratio, and the cutoff values of 202 prognostic indices were 6.698 and 6.833 for training and validation groups, 203 respectively. Based on the respective cutoff values, the two groups were stratified 204 into high-risk and low-risk groups, respectively. The Kaplan-Meier survival analysis 205 identified better OS among patients with low-risk group compared to those with high-risk group in training and validation groups (both P < 0.0001), confirming the 206 207 excellent discriminatory power of the nomogram (Figure. 6).

208

209 4. Discussion

The cardinal principle of management of patients with ICM and heart failure is to improve the health status-related quality of life and prolong lifespan. However, in light

of the dismal prognosis and scant randomized trails, divergent viewpoints have evolved among practitioners when treating this specific cohort. From this perspective, a rigorous selection process with the assistance of a specialized model covering universal and homogeneous variables among these patients to quantify the survival probability and optimize the prognostic discrimination should be implemented during counselling for clinical decision-making.

218 Several strengths of current nomogram are noteworthy. First, the current 219 nomogram may inform practice in an area where, up to now, there has been no 220 specialized model to predict overall survival for patients with ICM and heart failure. 221 Second, the enrolled variables including the evaluation of cardiac function, physical 222 status, comorbidities, demographics, and treatment type are multifaceted and easily 223 accessible, and on this premise, the current nomogram may provide ease of use in 224 the clinical setting. Third, considering the mutual causality between renal insufficiency 225 and heart failure, according to the recommendation of the Kidney Disease: Improving 226 Global Outcomes (KDIGO) organization, the estimated glomerular filtration rate 227 calculated by CKD-EPI equation was endorsed to precisely evaluate the renal function instead of creatinine or creatinine clearance rate.¹⁸ Fourth, it was reported 228 229 more than 70% of patients enrolled in the STICH trail had a severe burden of medical 230 co-morbidities at baseline, resulting in a ten-year mortality of approximately 70% in that cohort.¹⁹ Therefore, in the current study, the available medical co-morbid 231 232 conditions among these fragile patients were numerically quantified by the CCI in an 233 effort to provide the linear relation of risk between CCI score and OS. Fifth, in light of

234 the tangible elevated trend of net benefit shown with the extension of predicted nodal 235 time in DCA curves, the current nomogram can be used as a supplement to the STS 236 and EuroSCORE II risk models for predicting long-term survival. Taken as a whole, 237 the aforementioned strengths endowed practicality and generalizability to current 238 nomogram in clinical decision making with the engagement of clinicians and patients. 239 The twice risk of mortality for male compared to female deserves attention in 240 current study. Our result was in agreement with the finding of Pina et.al, who 241 identified a significant diminished all-cause mortality of 33% lower among female compared to male based on STICH trail.²⁰ The extended follow-up of the 242 243 MAIN-COMPARE (Ten-Year Outcomes of Stents Versus Coronary-Artery Bypass 244 Grafting for left Main Coronary-Artery Bypass Grafting for Left Main Coronary Artery 245 Disease) trail also revealed lower all-cause mortality and serious composite 246 outcomes at 10 years in female compared with male, and this difference was mainly driven by the higher event rate in male during the late period between 5 and 10 247 years.²¹ On the contrary, multiple lines of evidence have documented the poorer 248 249 prognosis of female compared to male due to various pathologic resultant such as medical co-morbid conditions, coronary microvascular dysfunction and diastolic filling 250 pattern.²²⁻²⁴. However, the 2021 ACC/AHA/SCAI guideline for coronary artery 251 252 revascularization highlighted that treatment decisions for patients with CAD requiring revascularization should be based on clinical indications, regardless of gender, race, 253 or ethnicity in an effort to mitigate disparities of care.² Yoon et.al reported that for 254 elderly patients with ICM who had a LVEF < 40% and left ventricular end diastolic 255

256 dimension > 55mm, different genders represented distinctly predominant series of risk factors of mortality.²⁵ On this premise, the aforementioned perspectives were not 257 258 inevitable in contrast to our result, and this lack of consistency should be expounded 259 in the setting of heterogeneous confounders with respect to study cohorts, genetics, neuroendocrine activation, anatomic complexity, medications prescribed and their 260 response to the disease process, and weights of variables.²⁶ Actually, continuing 261 262 debate still urges additional attempts to address a consensus surrounding the 263 interaction between gender and long-term survival in patients with CAD.

Several important variables with regard to the evaluation of cardiac function were 264 265 failed to contribute to the construction of the current nomogram after adjusting for baseline characteristics. Undoubtedly, the hierarchical thresholds of LVEF can be 266 267 used as a perfect tool to identify different subsets of patients with CAD, who have 268 various degrees of damaged left ventricular segmental systolic function. This 269 notwithstanding, it may not portend that they can invariably provide sufficient 270 efficiency to predict survival for some specific cohorts. The current study was in 271 agreement with several contemporary studies that had revealed inability of LVEF to shed light on short-term and long-term survival in patients with severe heart 272 failure.²⁷⁻³⁰ Withal, the underestimated LVEF caused by MR that accounted for 65% 273 274 patients in the current cohort might also contribute to the negative statistical power. Indeed, in addition to LVEF, a serious of cardiac substrate measured by 275 276 echocardiography that are independent of LVEF, such as E/A ratio, severity of MR, 277 sphericity index, ESVI, end-diastolic volume index, pulmonary artery pressure and

medRxiv preprint doi: https://doi.org/10.1101/2023.10.04.23296574; this version posted October 5, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

278 mechanical dyssynchrony, may typically present various degrees of adverse changes 279 accompanied by progressive left ventricular dilatation and adverse remodeling, and 280 have been identified as the independent risk factors for mortality.³⁰ However, due to 281 the large number of missing values in the STICH data, some of aforementioned 282 variables were not analyzed, thus adding residual confounding to current study.

283 Another indolent variable was NYHA heart failure classification which conferred a 284 graded risk of mortality in the univariate Cox model but was blunted in multivariate 285 analysis. This unexpected result ran counter to the prevailing wisdom of accumulated dogmas suggesting NYHA heart failure classification as a foundational criterion for 286 287 risk stratification. However, the variable subjectivity and poor reproducibility have 288 raised concerns about the accuracy of NYHA heart failure classification in evaluating 289 prognosis. The findings of Caraballo et al. who conducted secondary analyses of four 290 multicenter National Institutes of Health-funded heart failure clinical trials 291 demonstrated poor discrimination across the spectrum of functional impairment and unreliable prediction of survival, based on NYHA heart failure classification.³¹ Greene 292 293 et al. compared the NYHA heart failure classification and the Kansas City 294 Cardiomyopathy Questionnaire Overall Summary Score (KCCQ-OS) with respect to 295 clinically meaningful changes in health status over time, and found that changes in 296 NYHA heart failure classification failed to translated into a benefit of clinical outcomes with respect to all-cause mortality, heart failure hospitalization, and these two 297 composition.³² Obviously, the STICH trail inevitably suffered the aforementioned 298 299 limitations from the fact that patients were recruited from 99 medical centers in 22

300 countries.

301 The current study can provide actionable evidence for contemporary practice in the following aspects. First, our results enhanced the consensus that CABG in 302 conjunction with guideline-directed medical therapies could be the preferred 303 304 recommendation for patients with ICM and heart failure by reducing 20% risk of 305 all-cause mortality compared to medical therapy alone. Second, on the basis of 306 concern about the high weight of comorbidities in current nomogram, a 307 comprehensive multidisciplinary therapeutic is warranted and may potentially improve 308 the survival time. Third, given the reversibility of ischemic MR, strategies to reduce 309 the severity of MR are urgent in an effort to reduce the mortality, whether or not 310 CABG or medical therapy alone is selected. Fourth, the current nomogram in 311 conjunction with the STS and EuroSCORE II risk models may serve as a perfect tool 312 in clinical decision making with the engagement of clinicians and patients.

313 Our study cannot avoid certain inevitable limitations due to the post-hoc nature and 314 lack of external validation. Due to the large number of missing values, several vital 315 variables were not collected, and selection biases added insufficiently corrected residual confounding to current study. The small size of subgroups of MR and NYHA 316 317 heart failure classification can be translated into heterogeneity, compromising the 318 reliability of the nomogram. The fact that several medical co-morbidities were not 319 recorded in the STICH trail caused the underestimated CCI scores. Based on the 320 STICH protocol, the generalizability of current nomogram might not be suitable for 321 patients who have the conditions among exclusion criteria. Therefore, our results

322 should be interpreted with caution and external validation is warranted.

323

5. Conclusion

The current study developed a specified nomogram containing seven multifaceted and easily accessible variables to predict the OS for patients with ICM and heart failure, and provided information about multidisciplinary therapeutic that may prolong the survival time. This nomogram in conjunction with the STS and EuroSCORE II risk models may serve as a perfect tool in clinical decision making with the engagement of clinicians and patients.

331

Acknowledgments: Conception and design: Pengju Guo and Chang He. Acquisition of data: Pengju Guo. Analysis and interpretation of data: Pengju Guo and Chang He; Manuscript writing: Pengju Guo. Revision: Junlei LI, Youxu Jiang, Feng Wang, Jiaxiang Wang, Bin Lin, and Deguang Feng. All the authors listed have approved the manuscript that is enclosed and agree with its content.

337 **Sources of Funding:** None.

338 **Disclosures:** All authors have declared no conflicts of interest.

339

340 **References**

Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP,
 Chamberlain AM, Chang AR, Cheng S, Delling FN, et al. Heart Disease and
 Stroke Statistics-2020 Update: A Report From the American Heart Association.

| 344 | | Circulation. 2020;141:e139-e596. doi: 10.1161/CIR.0000000000000757 |
|-----|----|---|
| 345 | 2. | Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM, Bischoff |
| 346 | | JM, Bittl JA, Cohen MG, DiMaio JM, Don CW, et al. 2021 ACC/AHA/SCAI |
| 347 | | Guideline for Coronary Artery Revascularization: A Report of the American |
| 348 | | College of Cardiology/American Heart Association Joint Committee on Clinical |
| 349 | | Practice Guidelines. <i>Circulation</i> . 2022;145:e18-e114. doi: |
| 350 | | 10.1161/CIR.000000000001038 |
| 351 | 3. | Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, |
| 352 | | Byrne RA, Collet JP, Falk V, Head SJ, et al. 2018 ESC/EACTS Guidelines on |
| 353 | | myocardial revascularization. Eur Heart J. 2019;40:87-165. doi: |
| 354 | | 10.1093/eurheartj/ehy394 |
| 355 | 4. | Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, |
| 356 | | Drazner MH, Dunlay SM, Evers LR, et al. 2022 AHA/ACC/HFSA Guideline for |
| 357 | | the Management of Heart Failure: A Report of the American College of |
| 358 | | Cardiology/American Heart Association Joint Committee on Clinical Practice |
| 359 | | Guidelines. <i>Circulation</i> . 2022;145:e895-e1032. doi: |
| 360 | | 10.1161/CIR.000000000000000000000000000000000000 |
| 361 | 5. | Velazquez EJ, Lee KL, Jones RH, Al-Khalidi HR, Hill JA, Panza JA, Michler RE, |
| 362 | | Bonow RO, Doenst T, Petrie MC, et al. Coronary-Artery Bypass Surgery in |
| 363 | | Patients with Ischemic Cardiomyopathy. N Engl J Med. 2016;374:1511-1520. |
| 364 | | doi: 10.1056/NEJMoa1602001 |
| | | |

365 6. Wrobel K, Stevens SR, Jones RH, Selzman CH, Lamy A, Beaver TM, Djokovic

366 LT, Wang N, Velazquez EJ, Sopko G, et al. Influence of Baseline 367 Characteristics, Operative Conduct, and Postoperative Course on 30-Day Outcomes of Coronary Artery Bypass Grafting Among Patients With Left 368 Ventricular Dysfunction: Results From the Surgical Treatment for Ischemic 369 Heart Failure (STICH) Trial. Circulation. 2015;132:720-730. doi: 370 371 10.1161/CIRCULATIONAHA.114.014932

372 7. Crea F. Treatment of heart failure across the spectrum of left ventricular
arg

376 8. Pathak S, Lai FY, Miksza J, Petrie MC, Roman M, Murray S, Dearling J,

377 Perera D, Murphy GJ. Surgical or percutaneous coronary revascularization for

378 heart failure: an in silico model using routinely collected health data to emulate

a clinical trial. *Eur Heart J.* 2023;44:351-364. doi: 10.1093/eurheartj/ehac670

380 9. O'Brien SM, Feng L, He X, Xian Y, Jacobs JP, Badhwar V, Kurlansky PA,

381 Furnary AP, Cleveland JC, Jr., Lobdell KW, et al. The Society of Thoracic

- Surgeons 2018 Adult Cardiac Surgery Risk Models: Part 2-Statistical Methods
 and Results. Ann Thorac Surg. 2018;105:1419-1428. doi:
- 384 10.1016/j.athoracsur.2018.03.003
- Nashef SA, Roques F, Sharples LD, Nilsson J, Smith C, Goldstone AR,
 Lockowandt U. EuroSCORE II. *Eur J Cardiothorac Surg.* 2012;41:734-744;
 discussion 744-735. doi: 10.1093/ejcts/ezs043

| 388 | 11. | Takahashi K, Serruys PW, Fuster V, Farkouh ME, Spertus JA, Cohen DJ, Park |
|-----|-----|--|
| 389 | | SJ, Park DW, Ahn JM, Kappetein AP, et al. Redevelopment and validation of |
| 390 | | the SYNTAX score II to individualise decision making between percutaneous |
| 391 | | and surgical revascularisation in patients with complex coronary artery disease: |
| 392 | | secondary analysis of the multicentre randomised controlled SYNTAXES trial |
| 393 | | with external cohort validation. <i>Lancet</i> . 2020;396:1399-1412. doi: |
| 394 | | 10.1016/S0140-6736(20)32114-0 |

- Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM, Bischoff
 JM, Bittl JA, Cohen MG, DiMaio JM, Don CW, et al. 2021 ACC/AHA/SCAI
 Guideline for Coronary Artery Revascularization: Executive Summary: A
 Report of the American College of Cardiology/American Heart Association
 Joint Committee on Clinical Practice Guidelines. *Circulation*. 2022;145:e4-e17.
- 400 doi: 10.1161/CIR.000000000001039
- 13. Velazquez EJ, Lee KL, Deja MA, Jain A, Sopko G, Marchenko A, Ali IS,
- 402 Pohost G, Gradinac S, Abraham WT, et al. Coronary-artery bypass surgery in
- 403 patients with left ventricular dysfunction. *N Engl J Med*. 2011;364:1607-1616.
- 404 doi: 10.1056/NEJMoa1100356
- Velazquez EJ, Lee KL, O'Connor CM, Oh JK, Bonow RO, Pohost GM,
 Feldman AM, Mark DB, Panza JA, Sopko G, et al. The rationale and design of
 the Surgical Treatment for Ischemic Heart Failure (STICH) trial. *J Thorac Cardiovasc Surg.* 2007;134:1540-1547. doi: 10.1016/j.jtcvs.2007.05.069
- 409 15. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI,

- 410 Kusek JW, Eggers P, Van Lente F, Greene T, et al. A new equation to estimate
- 411 glomerular filtration rate. Ann Intern Med. 2009;150:604-612. doi:
 412 10.7326/0003-4819-150-9-200905050-00006
- Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying
 prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis.* 1987;40:373-383. doi: 10.1016/0021-9681(87)90171-8
- 416 17. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined
- 417 comorbidity index. J Clin Epidemiol. 1994;47:1245-1251. doi:
 418 10.1016/0895-4356(94)90129-5
- Stevens PE, Levin A, Kidney Disease: Improving Global Outcomes Chronic
 Kidney Disease Guideline Development Work Group M. Evaluation and
 management of chronic kidney disease: synopsis of the kidney disease:
 improving global outcomes 2012 clinical practice guideline. *Ann Intern Med.*2013;158:825-830. doi: 10.7326/0003-4819-158-11-201306040-00007
- 424 19. Ambrosy AP, Stevens SR, Al-Khalidi HR, Rouleau JL, Bouabdallaoui N,
 425 Carson PE, Adlbrecht C, Cleland JGF, Dabrowski R, Golba KS, et al. Burden
 426 of medical co-morbidities and benefit from surgical revascularization in
 427 patients with ischaemic cardiomyopathy. *Eur J Heart Fail.* 2019;21:373-381.
 428 doi: 10.1002/ejhf.1404
- Pina IL, Zheng Q, She L, Szwed H, Lang IM, Farsky PS, Castelvecchio S,
 Biernat J, Paraforos A, Kosevic D, et al. Sex Difference in Patients With
 Ischemic Heart Failure Undergoing Surgical Revascularization: Results From

| 432 the STICH Trial (Surgical Treatment for Ischer | nic Heart Failure). Circulation. |
|--|----------------------------------|
|--|----------------------------------|

- 433 2018;137:771-780. doi: 10.1161/CIRCULATIONAHA.117.030526
- 434 21. Yoon YH, Ahn JM, Lee JB, Kang DY, Park H, Jeong YJ, Lee J, Kim JH, Yang
- 435 Y, Hyun J, et al. Time-Dependent Impact of Sex on the Long-Term Outcomes
- 436 After Left Main Revascularization. *J Am Heart Assoc.* 2022;11:e021720. doi:
- 437 10.1161/JAHA.121.021720
- 438 22. Sun LY, Tu JV, Bader Eddeen A, Liu PP. Prevalence and Long-Term Survival
- 439 After Coronary Artery Bypass Grafting in Women and Men With Heart Failure
- and Preserved Versus Reduced Ejection Fraction. *J Am Heart Assoc.* 2018;7.
- 441 doi: 10.1161/JAHA.118.008902
- Taqueti VR, Di Carli MF. Coronary Microvascular Disease Pathogenic
 Mechanisms and Therapeutic Options: JACC State-of-the-Art Review. *J Am Coll Cardiol.* 2018;72:2625-2641. doi: 10.1016/j.jacc.2018.09.042
- Kwan AC, Wei J, Ouyang D, Ebinger JE, Merz CNB, Berman D, Cheng S. Sex
 differences in contributors to coronary microvascular dysfunction. *Front Cardiovasc Med.* 2023;10:1085914. doi: 10.3389/fcvm.2023.1085914
- Yoon HJ, Kim KH, Lee N, Park H, Kim HY, Cho JY, Ahn Y, Jeong MH.
 Sex-Specific Predictors of Long-Term Mortality in Elderly Patients with
 Ischemic Cardiomyopathy. *J Clin Med*. 2023;12. doi: 10.3390/jcm12052012
- 451 26. Mosca L, Barrett-Connor E, Wenger NK. Sex/gender differences in
 452 cardiovascular disease prevention: what a difference a decade makes.
 453 *Circulation.* 2011;124:2145-2154. doi:

454 10.1161/CIRCULATIONAHA.110.968792

- 455 27. Alla F, Briancon S, Juilliere Y, Mertes PM, Villemot JP, Zannad F. Differential clinical prognostic classifications in dilated and ischemic advanced heart 456 failure: EPICAL study. Am Heart 2000;139:895-904. 457 the J. doi: 10.1016/s0002-8703(00)90023-1 458
- Zhou Z, Zhuang X, Liu M, Jian B, Fu G, Liao X, Wu Z, Liang M. Left ventricular
 volume change and long-term outcomes in ischaemic cardiomyopathy with or
 without surgical revascularisation: A post-hoc analysis of a randomised
 controlled trial. *EClinicalMedicine*. 2022;53:101626. doi:
- 463 10.1016/j.eclinm.2022.101626
- Prior DL, Stevens SR, Holly TA, Krejca M, Paraforos A, Pohost GM, Byrd K,
 Kukulski T, Jones RH, Desvigne-Nickens P, et al. Regional left ventricular
 function does not predict survival in ischaemic cardiomyopathy after cardiac
- 467 surgery. *Heart*. 2017;103:1359-1367. doi: 10.1136/heartjnl-2016-310693
- 468 30. Kim KH, She L, Lee KL, Dabrowski R, Grayburn PA, Rajda M, Prior DL, Desvigne-Nickens P, Zoghbi WA, Senni M, et al. Incremental prognostic value 469 of echocardiography of left ventricular remodeling and diastolic function in 470 STICH trial. 471 Cardiovasc Ultrasound. 2020;18:17. doi: 472 10.1186/s12947-020-00195-1
- 473 31. Caraballo C, Desai NR, Mulder H, Alhanti B, Wilson FP, Fiuzat M, Felker GM,
 474 Piña IL, O'Connor CM, Lindenfeld J, et al. Clinical Implications of the New York
 475 Heart Association Classification. *Journal of the American Heart Association*.

- 476 2019;8. doi: 10.1161/jaha.119.014240
- 477 32. Greene SJ, Butler J, Spertus JA, Hellkamp AS, Vaduganathan M, DeVore AD,
- 478 Albert NM, Duffy CI, Patterson JH, Thomas L, et al. Comparison of New York
- 479 Heart Association Class and Patient-Reported Outcomes for Heart Failure
- 480 With Reduced Ejection Fraction. *JAMA Cardiology*. 2021;6. doi:
- 481 **10.1001/jamacardio.2021.0372**

482



Figure 1. Flow diagram of patient selection. eGFR = estimated glomerular filtration

rate; ESVI = end-systolic volume index; MR = mitral regurgitation; CAD = coronary

487 artery disease.

488

| Mariaklaa | Overall | Training group | Validation group | |
|---------------|------------|----------------|------------------|---------|
| Variables | (n = 940) | (n = 660) | (n = 280) | p value |
| Age (%) | | | | 0.564 |
| ≤ 50 | 139 (14.8) | 103 (15.6) | 36 (12.9) | |
| 51 - 60 | 384 (40.9) | 273 (41.4) | 111 (39.6) | |
| 61 - 70 | 284 (30.2) | 193 (29.2) | 91 (32.5) | |
| ≥ 71 | 133 (14.1) | 91 (13.8) | 42 (15.0) | |
| Gender (%) | | | | 0.603 |
| Male | 828 (88.1) | 579 (87.3) | 249 (88.9) | |
| Female | 112 (11.9) | 81 (12.3) | 31 (11.1) | |
| Ethnicity (%) | | | | 0.610 |
| White | 639 (68.0) | 452 (68.5) | 187 (66.8) | |
| Other | 301 (32.0) | 208 (31.5) | 93 (33.3) | |
| eGFR (%) | | | | 0.117 |

| > 60 ml/min per 1.73m ² | 697 (74.1) | 499 (75.6) | 198 (70.7) | |
|---|------------|------------|------------|-------|
| \leq 60 ml/min per 1.73m ² | 243 (25.9) | 161 (24.4) | 82 (29.3) | |
| NYHA heart failure (%) | | | | 0.603 |
| Class I | 117 (12.4) | 85 (12.9) | 32 (11.4) | |
| Class II | 493 (52.4) | 338 (51.2) | 155 (55.4) | |
| Class III | 310 (33.0) | 224 (33.9) | 86 (30.7) | |
| Class IV | 20 (2.2) | 13 (2.0) | 7 (2.5) | |
| CCI score (IQRs) | 5 (4-6) | 5 (4-6) | 5 (4-6) | 0.418 |
| Atrial flutter history (%) | | | | 0.785 |
| Yes | 115 (12.2) | 82 (12.4) | 33 (11.8) | |
| No | 825 (87.8) | 578 (87.6) | 247 (88.2) | |
| 6-minute walk (%) | | | | 0.305 |
| ≤ 300 m | 346 (36.8) | 236 (35.8) | 110 (39.3) | |
| > 300 m | 594 (63.2) | 424 (64.2) | 170 (60.7) | |

LVEF (%)

| ≤ 20% | 173 (18.4) | 117 (17.7) | 56 (20.0) | |
|---------------------------|------------|------------|------------|-------|
| 21 - 25% | 216 (23.0) | 154 (23.4) | 62 (22.1) | |
| 26 - 30% | 281 (29.9) | 191 (28.9) | 90 (32.2) | |
| 31 - 35% | 270 (28.7) | 198 (30.0) | 72 (25.7) | |
| ESVI (%) | | | | 0.965 |
| ≤ 60 ml/m ² | 263 (28.0) | 184 (27.9) | 79 (28.3) | |
| 61 - 90ml/m ² | 369 (39.2) | 258(39.1) | 111 (39.6) | |
| > 90 ml/m ² | 308 (32.8) | 218 (33.0) | 90 (32.1) | |
| Previous revascularizatio | n | | | 0.444 |
| (%) | | | | 0.441 |
| Yes | 137 (14.6) | 100 (15.2) | 37 (13.2) | |
| No | 803 (85.4) | 560 (84.8) | 243 (86.8) | |
| Mitral regurgitation (%) | | | | 0.865 |

| None or trace | 332 (35.3) | 235 (35.6) | 97 (34.6) | |
|--------------------|------------|------------|------------|-------|
| Mild | 435 (46.3) | 301 (45.6) | 134 (47.9) | |
| Moderate | 144 (15.3) | 102 (15.5) | 42 (15.0) | |
| Severe | 29 (3.1) | 22 (3.3) | 7 (2.5) | |
| Duke CAD Index (%) | | | | 0.471 |
| ≤ 40 | 277 (29.5) | 187 (28.3) | 90 (32.1) | |
| 41 - 70 | 345 (36.7) | 244 (37.0) | 101 (36.1) | |
| 71 - 100 | 318 (33.8) | 229 (34.7) | 89 (31.8) | |

Table 1. Baseline characteristics for entire cohort, training and validation groups. eGFR = estimated glomerular filtration rate; NYHA

492 = New York Heart Association; CCI = Charlson co-morbidity index; LVEF = left ventricular ejection fraction; ESVI = end-systolic

493 volume index; CAD = coronary artery disease.

| Verichler | | Univariable | | | Multivariable | |
|-----------|-------|---------------|---------|-------|---------------|---------|
| variables | HR | 95% CI | p value | HR | 95% CI | p value |
| Age | | | 0.001 | | | 0.391 |
| ≤ 50 | 1.0 | reference | | 1.0 | reference | |
| 51 - 60 | 1.331 | 0.971 – 1.826 | 0.076 | 0.997 | 0.708 – 1.405 | 0.987 |
| 61 - 70 | 1.745 | 1.263 – 2.411 | < 0.001 | 1.106 | 0.734 – 1.667 | 0.630 |
| ≥ 71 | 1.786 | 1.236 – 2.578 | 0.002 | 0.847 | 0.509 – 1.407 | 0.521 |
| Gender | | | | | | |
| Female | 1.0 | reference | | 1.0 | reference | |
| Male | 1.756 | 1.241 – 2.485 | 0.001 | 2.069 | 1.447 – 2.957 | < 0.001 |
| Ethnicity | | | | | | |
| White | 1.0 | reference | | | | |
| Other | 0.982 | 0.792 – 1.217 | 0.867 | | | |
| eGFR | | | | | | |

| > 60 ml/min per 1.73m ² | 1.0 | reference | | 1.0 | reference | |
|---|-------|---------------|---------|-------|---------------|-------|
| \leq 60 ml/min per 1.73m ² | 1.58 | 1.278 – 1.953 | < 0.001 | 1.342 | 1.051 – 1.713 | 0.018 |
| NYHA heart failure | | | 0.040 | | | 0.718 |
| Class I | 1.0 | reference | | 1.0 | reference | |
| Class II | 1.072 | 0.780 – 1.474 | 0.670 | 0.908 | 0.657 – 1.256 | 0.560 |
| Class III | 1.402 | 1.011 – 1.944 | 0.043 | 1.026 | 0.726 – 1.449 | 0.885 |
| Class IV | 1.689 | 0.827 – 3.449 | 0.150 | 1.106 | 0.527 – 2.319 | 0.790 |
| CCI score | 1.215 | 1.139 – 1.297 | < 0.001 | 1.175 | 1.063 – 1.300 | 0.002 |
| Atrial flutter history | | | | | | |
| No | 1.0 | reference | | 1.0 | reference | |
| Yes | 1.646 | 1.253 – 2.162 | < 0.001 | 1.315 | 0.985 – 1.756 | 0.064 |
| 6-minute walk | | | | | | |
| ≤ 300 m | 1.0 | reference | | 1.0 | reference | |
| > 300 m | 0.762 | 0.624 – 0.931 | 0.008 | 0.796 | 0.640 – 0.989 | 0.040 |

| LVEF | | | 0.050 | | | |
|--------------------------|-------|---------------|---------|-------|---------------|---------|
| ≤ 20% | 1.0 | reference | | | | |
| 21 - 25% | 0.931 | 0.696 – 1.247 | 0.633 | | | |
| 26 - 30% | 0.706 | 0.529 – 0.943 | 0.018 | | | |
| 31 - 35% | 0.760 | 0.572 – 1.009 | 0.058 | | | |
| ESVI | | | < 0.001 | | | 0.006 |
| ≤ 60 ml/m ² | 1.0 | reference | | 1.0 | reference | |
| 61 - 90ml/m ² | 1.458 | 1.132 – 1.877 | 0.003 | 1.441 | 1.109 – 1.874 | 0.006 |
| > 90 ml/m ² | 1.608 | 1.241 – 2.082 | < 0.001 | 1.517 | 1.161 – 1.981 | 0.002 |
| Previous | | | | | | |
| revascularization | | | | | | |
| No | 1.0 | reference | | | | |
| Yes | 1.043 | 0.799 – 1.362 | 0.758 | | | |
| Mitral regurgitation | | | < 0.001 | | | < 0.001 |

| None or trace | 1.0 | reference | | 1.0 | reference | |
|----------------|-------|---------------|---------|-------|---------------|---------|
| Mild | 1.148 | 0.918 – 1.436 | 0.226 | 1.181 | 0.941 – 1.482 | 0.151 |
| Moderate | 1.769 | 1.328 – 2.357 | < 0.001 | 1.467 | 1.091 – 1.971 | 0.011 |
| Severe | 2.747 | 1.676 – 4.503 | < 0.001 | 3.359 | 2.022 - 5.580 | < 0.001 |
| Duke CAD Index | | | 0.300 | | | |
| ≤ 40 | 1.0 | reference | | | | |
| 41 - 70 | 1.023 | 0.801 – 1.308 | 0.853 | | | |
| 71 - 100 | 1.180 | 0.923 – 1.510 | 0.187 | | | |
| Treatment | | | | | | |
| MED | 1.0 | reference | | 1.0 | reference | |
| CABG + MED | 0.764 | 0.628 – 0.930 | 0.007 | 0.802 | 0.655 – 0.981 | 0.032 |

Table 2. Univariate and multivariate Cox proportional hazards models of OS for patients with ischemic cardiomyopathy and heart
 498 failure in the training group. HR = hazards ratio; CI = confidence interval; eGFR = estimated glomerular filtration rate; NYHA = New

- 499 York Heart Association; CCI = Charlson co-morbidity index; LVEF = left ventricular ejection fraction; ESVI = end-systolic volume
- ⁵⁰⁰ index; CAD = coronary artery disease; CABG = coronary artery bypass grafting; MED = medical.

501



Figure 2. Nomogram for 1-year, 3-year, 5-year, and ten-year prediction of overall survival for patients with ischemic cardiomyopathy and heart failure. CABG = coronary artery bypass grafting; MED = medical; eGFR = estimated glomerular filtration rate; CCI = Charlson co-morbidity index; ESVI = end-systolic volume index.

508



Figure 3. Calibration curves of 1-year, 3-year, 5-year, and ten-year overall survival (OS) for patients with ischemic cardiomyopathy and heart failure. A: 1-year OS in training group; B: 3-year OS in the training group; C: 5-year OS in the training group; D: ten-year OS in the training group; E: 1-year OS in the validation group; F: 3-year OS in the validation group; G: 5-year OS in the validation group; H: ten-year OS in the validation group.

517



519

Figure 4. Time-dependent receiver operating characteristic curves of the overall survival (OS) in the training group for patients with ischemic cardiomyopathy and heart failure. A: 1-year OS; B: 3-year OS; C: 5-year OS; D: ten-year OS; E: time-dependent area under curve (AUC).

524



Figure 5. Decision Curve Analysis of the nomogram in training group (A: 1-year OS, B: 3-year OS, C: 5-year OS, D: ten-year OS) and verification group (E: 1-year OS, F: 3-year OS, G: 5-year OS, H: ten-year OS). The horizontal black solid lines assumed all cases were alive, and the oblique gray solid lines assumed all cases were dead. The black dash lines represented net benefit of the model during the application in clinical decision-making. OS = overall survival.

- 533
- 534
- 535



Figure 6. Kaplan-Meier survival analysis of overall survival among patients with 537 low-risk group and patients with high-risk group in training and validation groups. A: 538

training group; B: validation group. 539